BioClean P-Zero™ - Excellent Cytotoxic Protection
Part of the BioClean Chemo Safety Wear range BioClean P-Zero? sterile cleanroom gloves are made from polychloroprene, provide exceptional cytotoxic protection, are antistatic and have outstanding tactility and grip.
BioClean P-Zero™ - Excellent Cytotoxic Protection
BioClean P-Zero™ (BPZS) sterile gloves provide exceptional cytotoxic protection, are antistatic and have outstanding tactility and grip.
The BioClean™ Chemo Safety Wear range, the P-Zero are hand-specific 300mm (12”) latex-free, powder-free, natural-coloured gloves featuring a textured surface and beaded cuff for strength and stability on the wrist. Packed in a non-particulating EasyTear™ pouch, they are ISO Class 4 and EU GMP Grade A compatible and available in sizes 6.0 to 9.0 (including half sizes.)
All BioClean Chemo Safety Wear gloves are tested against the most stringent standard ASTM D6978-05 (standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs) which is 100 times more stringent than its European counterpart EN 374-3:2003, meaning BioClean P-Zero gloves are the safe choice to make.
Contact Details:
Nitritex Ltd
Minton Enterprise Park, Oaks Drive
Newmarket, Suffolk, CB8 7YY
www.bioclean.cominfo@bioclean.comTel: +44 1638 663338
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
